SEC Tracker
Get the app

Annovis Bio ANVS

Annovis Bio reports $2.8M cash as of Sept 30, 2026

Item 2.02 Reports results, Item 7.01 Investor disclosure, Item 8.01 Other events

Form
8-K
Filed
Importance
Major
  1. Preliminary cash and cash equivalents of $2.8 million as of Sept 30, 2026
  2. Interim financial statements for three and nine months ended Sept 30, 2026 not yet available
  3. Estimates subject to change after financial closing procedures

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Annovis Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Abvc Biopharma ABVC public float $37M, Jun 30, 2025
  2. Karyopharm Therapeutics KPTI public float $37M, Jun 30, 2025
  3. Grace Therapeutics GRCE public float $35M, Sep 30, 2025
  4. BriaCell Therapeutics BCTX public float $37M, Jan 30, 2026
  5. Atara Biotherapeutics ATRA public float $39M, Jun 30, 2025